STADA Arzneimittel AG
http://www.stada.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STADA Arzneimittel AG
Stada Will Continue To Invest To Drive Growth
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Stada’s Goldschmidt Looks To Take Consumer Health Global
Stada CEO Peter Goldschmidt tells HBW Insight about his ambition to enter the US consumer health market as part of a push to take the business global.
Celltrion Strikes $278m Deal With Takeda
Celltrion has bought a portfolio of selected products in the Asia-Pacific region from Takeda, marking a foray into small-molecule drugs.
Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Bain Capital
- BIOCEUTICALS Arzneimittel AG
- Britannia Pharmaceuticals Limited
- Cinven
- Forum Bioscience Holdings, Ltd.
- Laboratorio Vannier S.A.
- Nidda Healthcare
- STADAPHARM GmbH